Canaccord Genuity Maintains a 'Buy' on AVEO Pharmaceuticals (AVEO); ODAC Vote Could Shape Future RCC Treatment Landscape
Tweet
Share
E-mailGet Alerts AVEO Hot Sheet
Price: $15.00 --0%
Rating Summary:
4 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
4 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on AVEO Pharmaceuticals (NASDAQ: AVEO) price target of $28.00.
Canaccord analyst, George Farmer, said, "Based on compelling data from the AXIS trial reported at ASCO last June, we believe axitinib will be recommended for broad treatment, including use in front-line disease. We believe the Street shares this view and already sees axitinib as a potentially meaningful competitor to tivozanib, which AVEO management intends to position in front-line RCC as well. We expect minimal impact on AVEO shares if ODAC follows through. Briefing documents are expected for release on Monday, December 5."
"Ahead of a December 7 ODAC meeting to discuss the merits of the NDA for Pfizer’s axitinib, a potential competitor to AVEO’s tivozanib in advanced renal cell carcinoma (RCC), we maintain our rating."
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $14.99 yesterday.
Canaccord analyst, George Farmer, said, "Based on compelling data from the AXIS trial reported at ASCO last June, we believe axitinib will be recommended for broad treatment, including use in front-line disease. We believe the Street shares this view and already sees axitinib as a potentially meaningful competitor to tivozanib, which AVEO management intends to position in front-line RCC as well. We expect minimal impact on AVEO shares if ODAC follows through. Briefing documents are expected for release on Monday, December 5."
"Ahead of a December 7 ODAC meeting to discuss the merits of the NDA for Pfizer’s axitinib, a potential competitor to AVEO’s tivozanib in advanced renal cell carcinoma (RCC), we maintain our rating."
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $14.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lowe's (LOW) PT Lowered to $275 at Guggenheim
- Ross Stores, Inc. (ROST) PT Raised to $239 at UBS on Q2 Earnings Beat
- Baird Starts Eaton Corporation (ETN) at Outperform
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
